Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: A promising approach for the treatment of prostate cancer

Genetic Vaccines and Therapy

Volumn 6, Issue , 2008, Pages

  Sousa Canavez, Juliana M ^a   Canavez, Flavio C ^a   Leite, Kátia R M ^a,b   Camara Lopes, Luiz H ^a  

^a Genoa Biotecnologia SA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD86 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; GLYCOPROTEIN P 15095; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; T6 ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CELL MATURATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DRUG RESEARCH; ELECTROPORATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; METASTASIS POTENTIAL; MONOCYTE; PHENOTYPE; PROSTATE CANCER; RNA EXTRACTION; RNA TRANSCRIPTION; VACCINE PRODUCTION;

EID: 40349087264     PISSN: None     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-6-2     Document Type: Article

References (23)

1. Instituto Nacional do Câncer http://www.inca.gov.br/estimativa/ 2006/
2. Ali AS Hamdy FC: The spectrum ofFprostate cancer care: from curative intent to palliation. Curr Urol Rep 2007, 8(3):245-52. 10.1007/ s11934-007-0013-9 17459275
3. Taplin ME: Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol 2003, 5(Suppl 2):S3-S13. 16986044
4. Pound CR Partin AW Eisenberger MA Chan DW Pearson JD Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1642-5. 10.1001/jama.281.17.1591 10235160
5. Hadaschik BA Gleave ME: Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 2007, 25:413-9. 17826663
6. Mosca PJ Lyerly HK Clay TM Morse MA Lyerly HK: Dendritic cell vaccines. Front Biosci 2007, 12:4050-60. 10.2741/2371 17485358
7. Osada T Clay TM Woo CY Morse MA Lyerly HK: Dendritic cell-based immunotherapy. Int Rev Immunol 2006, 25(5-6):377-413. 10.1080/ 08830180600992456 17169781
8. Gilboa E: DC-based cancer vaccines. J Clin Invest 2007, 117(5):1195-203. 1857263 17476349 10.1172/JCI31205
9. Barbuto JAM Ensina LFC Neves AR Bergamini-Santos PC Leite KRM Marques R Costa F Martins SC Câmara-Lopes LH Buzaid AC: Dendritic cell-tumor hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 2007, 53:1111-18. 10.1007/s00262-004-0551-7
10. Thomas-Kaskel AK Waller CF: Schultze-Seemann W Veelken H Immunotherapy with dendritic cells for prostate cancer. Int J Cancer 2007, 121(3):467-73. 10.1002/ijc.22859 17514654
11. Boczkowski D Nair SK Nam JH Lyerly HK Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996, 184:465-72. 10.1084/jem.184.2.465 8760800
12. Banchereau J Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-52. 10.1038/32588 9521319
13. Salgaller ML Lodge PA McLean JG Tjoa BA Loftus DJ Ragde H Kenny GM Rogers M Boynton AL Murphy GP: Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 1998, 35:144-51. 10.1002/ (SICI)1097-0045(19980501)35:2<144::AID-PROS8>3.0.CO;2-J 9568678
14. Murphy GP Tjoa BA Simmons SJ Jarisch J Bowes VA Ragde H Rogers M Elgamal A Kenny GM Cobb OE Ireton RC Troychak MJ Salgaller ML Boynton AL: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999, 38:73-8. 10.1002/ (SICI)1097-0045(19990101)38:1<73::AID-PROS9>3.0.CO;2-V 9973112
15. Callegari-Jacques SM Grattapaglia D Salzano FM Salamoni SP Crossetti SG Ferreira ME HutS MH: Historical genetics: spatiotemporal analysis of the formation of the Brazilian population. Am J Hum Biol 2003, 15:824-34. 10.1002/ajhb.10217 14595874
16. Abe-Sandes K Silva WA Jr Zago MA: Heterogeneity of the Y chromosome in Afro-Brazilian populations. Hum Biol 2004, 76:77-86. 10.1353/ hub.2004.0014 15222681
17. Van Tendeloo VF Ponsaerts P Berneman ZN; mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther 2007, 9:423-31. 17932806
18. Heiser A Coleman D Dannull J Yancey D Maurice MA Lallas CD Dahm P Niedzwiecki D Gilboa E Vieweg J: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002, 109:409-17. 150859 11828001 10.1172/JCI200214364
19. Su Z Dannull J Yang BK Dahm P Coleman D Yancey D Sichi S Niedzwiecki D Boczkowski D Gilboa E Vieweg J: Telomerase mRNA-transfected Dendritic Cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005, 174(6):3798-807. 15749921
20. de Vries IJ Lesterhuis WJ Scharenborg NM Engelen LP Ruiter DJ Gerritsen MJ Croockewit S Britten CM Torensma R Adema GJ Figdor CG Punt CJ: Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003, 9(14):5091-100. 14613986
21. McIlroy D Gregoire M: Optimizing dendritic cell-based anticancer immunotherapy: Maturation state does have clinical impact. Cancer Immunol Immunother 2003, 52:583-91. 10.1007/s00262-003-0414-7 12827310
22. Tjoa BA Simmons SJ Bowes VA Ragde H Rogers M Elgamal A Kenny GM Cobb OE Ireton RC Troychak MJ Salgaller ML Boynton AL Murphy GP: Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998, 36(1):39-44. 10.1002/ (SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6 9650914
23. Neves AR Ensina LFC Anselmo LB Leite KRM Buzaid AC Camara-Lopes LH Barbuto JAM: Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunol Immunother 2005, 54:61-66. 10.1007/ s00262-004-0550-8 15693140